← Leaderboards
Keith A Webster
University Of Miami School Of Medicine
$10,328,678
Attributed
$13,091,999
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$13,091,999 · 7
By mechanism
R01$9,092,022 · 4
R24$3,471,977 · 1
R21$303,000 · 1
R43$225,000 · 1
Top collaborators
- Wei Li5 shared
- Roberto Irenardo Vazquez Padron4 shared
- Omaida C Velazquez4 shared
- Hong Tian1 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Roberto Irenardo Vazquez Padron$5,595,653
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistIschemiaCellsMediatingPhosphotransferasesHypoxiaMolecularPathway InteractionsApoptosisAngiogenesisIn VivoReportingBlood VesselsReperfusion TherapyIn VitroProteinsCardiac MyocytesVascular Endothelial Growth FactorsAnimal ModelRegulationStem CellsEventMouse ModelRepaired
Grant awards (33)
A selective angiogenesis blocker to treat retinopathy of prematurity$76,000
R24 · FY2022 · EY
A selective angiogenesis blocker to treat retinopathy of prematurity$1,838,570
R24 · FY2020 · EY
Anti-angiogenic gene therapy of ocular vascular diseases$225,000
R43 · FY2020 · EY
A selective angiogenesis blocker to treat retinopathy of prematurity$1,360,447
R24 · FY2019 · EY
A selective angiogenesis blocker to treat retinopathy of prematurity$196,960
R24 · FY2019 · EY
C-Kit in atherosclerosis$466,401
R01 · FY2018 · HL
C-Kit in atherosclerosis$383,750
R01 · FY2017 · HL
C-Kit in Atherosclerosis$82,098
R01 · FY2017 · HL
C-Kit in atherosclerosis$383,750
R01 · FY2016 · HL
Micro-RNA Reprogrammed Human CD34 Stem Cells for Cardiovascular Disease Therapy$386,097
R01 · FY2014 · HL · contact PI
Micro-RNA Reprogrammed Human CD34 Stem Cells for Cardiovascular Disease Therapy$438,424
R01 · FY2013 · HL · contact PI
Micro-RNA reprogrammed human CD34 stem cells for cardiovascular disease therapy$393,977
R01 · FY2012 · HL · contact PI
Micro-RNA reprogrammed human CD34 stem cells for cardiovascular disease therapy$66,555
R01 · FY2012 · HL · contact PI
Mechanisms of action and activation of the death-inducing protein Bnip3$420,750
R01 · FY2011 · HL · contact PI
Micro-RNA reprogrammed human CD34 stem cells for cardiovascular disease therapy$393,975
R01 · FY2011 · HL · contact PI
JNK exacerbates ischemia/reperfusion injury in hyperglycemic subjects.$478,125
R01 · FY2010 · HL · contact PI
Mechanisms of action and activation of the death-inducing protein Bnip3$420,750
R01 · FY2010 · HL · contact PI
Mechanisms of action and activation of the death-inducing protein Bnip3$12,531
R01 · FY2010 · HL · contact PI
JNK exacerbates ischemia/reperfusion injury in hyperglycemic subjects.$478,125
R01 · FY2009 · HL · contact PI
Mechanisms of action and activation of the death-inducing protein Bnip3$382,500
R01 · FY2009 · HL · contact PI
Mechanisms of action and activation of the death-inducing protein Bnip3$382,500
R01 · FY2008 · HL · contact PI
Mechanisms of action and activation of the death-inducing protein Bnip3$382,292
R01 · FY2007 · HL · contact PI
Regulated Therapeutic Angiogenesis: for Ischemic Disease$365,078
R01 · FY2006 · HL · contact PI
Pathways of Apoptosis in Hypoxic Cardiac Myocytes$328,094
R01 · FY2006 · HL · contact PI
Regulated Therapeutic Angiogenesis: for Ischemic Disease$373,931
R01 · FY2005 · HL
Pathways of Apoptosis in Hypoxic Cardiac Myocytes$336,056
R01 · FY2005 · HL
Regulated Therapeutic Angiogenesis: for Ischemic Disease$372,966
R01 · FY2004 · HL
Pathways of Apoptosis in Hypoxic Cardiac Myocytes$335,091
R01 · FY2004 · HL
Pathways of Apoptosis in Hypoxic Cardiac Myocytes$367,364
R01 · FY2003 · HL
Regulated Therapeutic Angiogenesis: for Ischemic Disease$366,334
R01 · FY2003 · HL
Therapeutic angiogenesis to treat ischemic disorders$151,500
R21 · FY2002 · HL
Therapeutic angiogenesis to treat ischemic disorders$151,500
R21 · FY2001 · HL
CARDIOCYTE RESPONSES TO HYPOXIA$294,508
R01 · FY2000 · HL